[go: up one dir, main page]

KR900002795A - 하이브리드 단백질c 작제물 및 그들의 제조방법 - Google Patents

하이브리드 단백질c 작제물 및 그들의 제조방법 Download PDF

Info

Publication number
KR900002795A
KR900002795A KR1019890011316A KR890011316A KR900002795A KR 900002795 A KR900002795 A KR 900002795A KR 1019890011316 A KR1019890011316 A KR 1019890011316A KR 890011316 A KR890011316 A KR 890011316A KR 900002795 A KR900002795 A KR 900002795A
Authority
KR
South Korea
Prior art keywords
protein
gene construct
medicament
host cell
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890011316A
Other languages
English (en)
Inventor
다모쯔 하시모또
미끼꼬 다까하시
Original Assignee
아다찌 가즈오
훽스트 제펜 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다찌 가즈오, 훽스트 제펜 리미티드 filed Critical 아다찌 가즈오
Publication of KR900002795A publication Critical patent/KR900002795A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

내용 없음

Description

하이브리드 단백질 C 작제물 및 그들의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제 1 도는 pCs8의 제한지도이다,
제 2 도는 pCs1의 제한지도이다,
제 3 도는 pHSG293의 제한지도이다.

Claims (9)

  1. r-카복실화된 글루탐산 잔기를 갖는 사람 단백질 C의 아미노 말단 영역(Gla 도메인)이 소 단백질 C의 Cla 도메인에 의해, 또는 칼슘 결합 활성 및/또는 증강된 단백질 C의 활성면에서의 상기 소 단백질 서열의 등가물에 의해 대체됨을 특징으로 하는 사람 단백질 C의 유도체.
  2. 제 1 항에 있어서, 처음 43개의 아미노산이 소단백질 C의 아미노산임을 특징으로 하는 단백질.
  3. 제 1 또는 2항에 따른 단백질을 암호화하는 DNA.
  4. 제 3 항에 따른 DNA를 포함하는 유전자 구조물.
  5. 제 4 항에 따른 유전자 구조물을 포함하는 숙주 세포.
  6. 제 4 항에 따른 유전자 구조물을 숙주 세포 내에서 발현시킴을 특징으로 하여 제1 또는 2항에 따른 단백질을 제조하는 방법.
  7. 제1 또는 2항에 따른 단백질을 포함하는 약제.
  8. 치료시 사용하기 위한 제1 또는 2항에 따른 단백질 또는 제 6 항에 따른 방법으로 수득할 수 있는 단백질.
  9. 혈액 응고 질환 치료용 약제의 제조를 위한 제1 또는 제2항에 따른 단백질의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011316A 1988-08-09 1989-08-09 하이브리드 단백질c 작제물 및 그들의 제조방법 Withdrawn KR900002795A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63-197144 1988-08-09
JP63197144A JPH0246296A (ja) 1988-08-09 1988-08-09 雑種プロテインｃ及びその製造方法

Publications (1)

Publication Number Publication Date
KR900002795A true KR900002795A (ko) 1990-03-23

Family

ID=16369490

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011316A Withdrawn KR900002795A (ko) 1988-08-09 1989-08-09 하이브리드 단백질c 작제물 및 그들의 제조방법

Country Status (9)

Country Link
EP (1) EP0354504A2 (ko)
JP (1) JPH0246296A (ko)
KR (1) KR900002795A (ko)
AU (1) AU3937289A (ko)
DK (1) DK388789A (ko)
FI (1) FI893724L (ko)
IL (1) IL91234A0 (ko)
NO (1) NO893196L (ko)
PT (1) PT91391A (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
JPH04127174U (ja) * 1991-05-09 1992-11-19 株式会社シマノ 釣り用リール
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) * 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6998122B1 (en) 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
JP2003521919A (ja) 2000-02-02 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
WO2002070681A1 (en) * 2001-03-02 2002-09-12 T.A.C. Thrombosis And Coagulation Ab Protein c variants
RU2004134726A (ru) 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
CA2519873C (en) 2003-03-20 2012-12-18 Maxygen Holdings Ltd. Fvii or fviia variants
ATE458057T1 (de) 2003-06-19 2010-03-15 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne

Also Published As

Publication number Publication date
DK388789A (da) 1990-02-10
AU3937289A (en) 1990-04-12
FI893724A0 (fi) 1989-08-07
EP0354504A2 (en) 1990-02-14
NO893196D0 (no) 1989-08-08
FI893724A7 (fi) 1990-02-10
IL91234A0 (en) 1990-03-19
FI893724L (fi) 1990-02-10
JPH0246296A (ja) 1990-02-15
NO893196L (no) 1990-02-12
PT91391A (pt) 1990-03-08
DK388789D0 (da) 1989-08-08

Similar Documents

Publication Publication Date Title
KR900002795A (ko) 하이브리드 단백질c 작제물 및 그들의 제조방법
ATE110782T1 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
KR890000666A (ko) 응고활성을 갖는 인자 viii:c-형 분자
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
DE59611371D1 (de) Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen
KR900700116A (ko) 뼈-유도 단백질
EP0278776A3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
JPS6485096A (en) Hybrid human protein c and biotechnological synthesis thereof
NO904378L (no) Fremgangsmaate for fremstilling av et modifisert protein for terapeutisk anvendelse.
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
ATE59962T1 (de) Thrombin bindender stoff und verfahren zu seiner herstellung.
NO971059L (no) Modifiserte human-C3-proteiner
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
EP0181634A3 (en) Synthetic gene for human lysozyme
ATE111525T1 (de) Plasminogenaktivator-varianten und verfahren zu ihrer herstellung.
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
KR890008317A (ko) 유전학적 조작에 의한 응고억제성 단백질 pp4의 제조방법
DK0421949T3 (da) Kemisk modificerede allergener og fremgangsmåde til deres fremstilling
HUP9901161A2 (hu) Módosított aktivitású hibrid VIII. faktor
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
EP0680763A3 (en) Stable preparation for the treatment of blood coagulation disorders comprising an activated coagulation factor and lipid vesicles
FI99114B (fi) Menetelmä tyvikalvoproteiinien eristämiseksi ihmis- ja eläinkudoksista
ES544175A0 (es) Un procedimiento para preparar un material polimero hidrofilo basado en polisacaridos polipeptidos y -o proteinas y derivados acrilicos hidrofilos.
PT88913A (pt) Processo para a preparacao da proteina pp4-x anticoagulante
FI954889A0 (fi) Proteiini, jolla on TPO-aktiviteetti

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890809

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid